UPSTREAM BIO INC
UPBNASDAQTrading Snapshot
- Day Range
- $7.03 – $7.19
- 52-Week Range
- $5.85 – $33.68
- Volume
- $1.89B
- Avg Volume
- $1.82B
- Shares Outstanding
- 54.4M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $773,000
- P/E Ratio
- —
- P/S Ratio
- 119.8x
- EPS (TTM)
- $-2.90
- Dividend Yield
- —
Why Investors Own UPB
- ✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About UPSTREAM BIO INC
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track – – Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 – – Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications – WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Upstream Bio,
Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.